Key Points
- Major shareholder Chidozie Ugwumba conducted a wave of insider selling between Dec. 31 and Jan. 15, offloading about 133,292 shares (~$725,500), including 12,563 shares on Jan. 15 at $5.10, and now holds 650,298 shares after a 1.9% reduction from the latest sale.
- Stock and outlook: CLNN is trading near $5.05 (below its 50‑day $7.14 and 200‑day $6.45 averages) with a market cap of ~$54.8M, recently missed EPS expectations (‑$0.85 vs. ‑$0.60) and minimal revenue, yet analysts have a consensus "Moderate Buy" and a $32.60 price target.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 12,563 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $5.10, for a total transaction of $64,071.30. Following the completion of the transaction, the insider owned 650,298 shares in the company, valued at $3,316,519.80. This trade represents a 1.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total transaction of $100,459.52.
- On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total transaction of $127,653.45.
- On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total transaction of $179,877.50.
- On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $56,900.25.
- On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total transaction of $19,457.55.
- On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The stock was sold at an average price of $6.29, for a total value of $24,770.02.
- On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total value of $18,790.44.
- On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total value of $34,451.03.
- On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The shares were sold at an average price of $5.73, for a total value of $23,005.95.
- On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total value of $76,081.95.
Clene Stock Down 1.2%
CLNN stock opened at $5.05 on Friday. The business's 50-day moving average price is $7.14 and its 200-day moving average price is $6.45. The stock has a market cap of $54.79 million, a P/E ratio of -1.49 and a beta of 0.87. Clene Inc. has a twelve month low of $2.28 and a twelve month high of $13.50.
Clene (NASDAQ:CLNN - Get Free Report) last released its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. On average, equities research analysts expect that Clene Inc. will post -5.19 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. D. Boral Capital restated a "buy" rating and set a $23.00 target price on shares of Clene in a research note on Friday, January 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Clene in a report on Friday, January 9th. Benchmark restated a "buy" rating on shares of Clene in a research report on Thursday, December 4th. Finally, UBS Group reiterated a "buy" rating on shares of Clene in a research report on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Clene has an average rating of "Moderate Buy" and a consensus price target of $32.60.
Read Our Latest Stock Analysis on Clene
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in CLNN. Jones Financial Companies Lllp bought a new stake in shares of Clene in the third quarter worth about $29,000. Jane Street Group LLC purchased a new position in Clene during the 2nd quarter valued at approximately $47,000. Lunt Capital Management Inc. increased its stake in Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock worth $199,000 after acquiring an additional 21,217 shares during the last quarter. Finally, Scoggin Management LP raised its holdings in shares of Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company's stock worth $558,000 after acquiring an additional 42,750 shares in the last quarter. Institutional investors own 23.28% of the company's stock.
About Clene
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
